(Q39402922)

11 September 2017

title

Up-regulation of hexokinaseII in myeloma cells: targeting myeloma cells with 3-bromopyruvate (English)

1 reference

11 September 2017

Ayako Nakano

1

1 reference

11 September 2017

Hirokazu Miki

2

1 reference

11 September 2017

Shingen Nakamura

3

1 reference

11 September 2017

Takeshi Harada

4

1 reference

11 September 2017

Asuka Oda

5

1 reference

11 September 2017

Hiroe Amou

6

1 reference

11 September 2017

Shiro Fujii

7

1 reference

11 September 2017

Kumiko Kagawa

8

1 reference

11 September 2017

Kyoko Takeuchi

9

1 reference

11 September 2017

Shuji Ozaki

10

1 reference

11 September 2017

Toshio Matsumoto

11

1 reference

11 September 2017

Masahiro Abe

12

1 reference

11 September 2017

publication date

1 February 2012

1 reference

Journal of Bioenergetics and Biomembranes

11 September 2017

published in

1 reference

11 September 2017

volume

44

1 reference

11 September 2017

issue

1

1 reference

11 September 2017

page(s)

31-38

1 reference

https://scigraph.springernature.com/pub.10.1007/s10863-012-9412-9

11 September 2017

exact match

0 references

cites work

Targeting the interplay between myeloma cells and the bone marrow microenvironment in myeloma

1 reference

https://api.crossref.org/works/10.1007%2FS10863-012-9412-9

Osteoclasts enhance myeloma cell growth and survival via cell-cell contact: a vicious cycle between bone destruction and myeloma expansion

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10863-012-9412-9

The serine/threonine kinase Pim-2 is a novel anti-apoptotic mediator in myeloma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10863-012-9412-9

Regulation of cancer cell metabolism

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10863-012-9412-9

Role of mitochondria-associated hexokinase II in cancer cell death induced by 3-bromopyruvate

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10863-012-9412-9

The clinical and therapeutic implications of cancer stem cell biology

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10863-012-9412-9

ABC transporters, drug resistance, and cancer stem cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10863-012-9412-9

Lactate shuttles at a glance: from physiological paradigms to anti-cancer treatments

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10863-012-9412-9

IL-3 is a potential inhibitor of osteoblast differentiation in multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10863-012-9412-9

ABC transporters in cancer: more than just drug efflux pumps.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10863-012-9412-9

Fibroblast activation protein (FAP) is upregulated in myelomatous bone and supports myeloma cell survival

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10863-012-9412-9

Myeloma cells block RUNX2/CBFA1 activity in human bone marrow osteoblast progenitors and inhibit osteoblast formation and differentiation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10863-012-9412-9

Inhibition of early apoptotic events by Akt/PKB is dependent on the first committed step of glycolysis and mitochondrial hexokinase

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10863-012-9412-9

GM-CSF and IL-4 induce dendritic cell differentiation and disrupt osteoclastogenesis through M-CSF receptor shedding by up-regulation of TNF-alpha converting enzyme (TACE).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10863-012-9412-9

Tumor metabolism of lactate: the influence and therapeutic potential for MCT and CD147 regulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10863-012-9412-9

Apoptosis-inducing antitumor efficacy of hexokinase II inhibitor in hepatocellular carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10863-012-9412-9

Glucose catabolism in the rabbit VX2 tumor model for liver cancer: characterization and targeting hexokinase

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10863-012-9412-9

Aerobic glycolysis: meeting the metabolic requirements of cell proliferation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10863-012-9412-9

Multiple myeloma: biology of the disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10863-012-9412-9

Glucose catabolism in cancer cells. Isolation, sequence, and activity of the promoter for type II hexokinase

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10863-012-9412-9

Hexokinase II: cancer's double-edged sword acting as both facilitator and gatekeeper of malignancy when bound to mitochondria

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10863-012-9412-9

Hexokinase-2 bound to mitochondria: cancer's stygian link to the "Warburg Effect" and a pivotal target for effective therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10863-012-9412-9

Glycolysis inhibition inactivates ABC transporters to restore drug sensitivity in malignant cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10863-012-9412-9

Myeloma cells suppress bone formation by secreting a soluble Wnt inhibitor, sFRP-2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10863-012-9412-9

The cancer cell's "power plants" as promising therapeutic targets: an overview

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10863-012-9412-9

Warburg, me and Hexokinase 2: Multiple discoveries of key molecular events underlying one of cancers' most common phenotypes, the "Warburg Effect", i.e., elevated glycolysis in the presence of oxygen

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10863-012-9412-9

Targeting the bone microenvironment in multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10863-012-9412-9

Remarkably enhanced expression of the type II hexokinase in rat hepatoma cell line AH130.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10863-012-9412-9

PI-3-K and AKT: Onto the mitochondria

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10863-012-9412-9

Targeting multidrug resistance in cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10863-012-9412-9

Tgf-Beta inhibition restores terminal osteoblast differentiation to suppress myeloma growth

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10863-012-9412-9

The role of the Wnt-signaling antagonist DKK1 in the development of osteolytic lesions in multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10863-012-9412-9

Hexokinase 2 is a key mediator of aerobic glycolysis and promotes tumor growth in human glioblastoma multiforme

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10863-012-9412-9

Advances in the understanding of myeloma bone disease and tumour growth

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10863-012-9412-9

Cancer and the microenvironment: myeloma-osteoclast interactions as a model

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10863-012-9412-9

Atacicept (TACI-Ig) inhibits growth of TACI(high) primary myeloma cells in SCID-hu mice and in coculture with osteoclasts

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10863-012-9412-9

HGF inhibits BMP-induced osteoblastogenesis: possible implications for the bone disease of multiple myeloma.

21 January 2018

1 reference

12 December 2020

Role for macrophage inflammatory protein (MIP)-1alpha and MIP-1beta in the development of osteolytic lesions in multiple myeloma

1 reference

12 December 2020

Macrophage inflammatory protein 1-alpha is a potential osteoclast stimulatory factor in multiple myeloma

1 reference

12 December 2020

BAFF and APRIL as osteoclast-derived survival factors for myeloma cells: a rationale for TACI-Fc treatment in patients with multiple myeloma

1 reference

12 December 2020

Effect of 2-deoxy-D-glucose on various malignant cell lines in vitro.

1 reference

12 December 2020

Determination of P-glycoprotein, MDR-related protein 1, breast cancer resistance protein, and lung-resistance protein expression in leukemic stem cells of acute myeloid leukemia

1 reference

12 December 2020

10.1007/S10863-012-9412-9

Identifiers

DOI

1 reference

11 September 2017

1 reference